【摘要】

【摘要】 目的 分析齐拉西酮联合心理治疗对伴抑郁症状精神分裂症患者临床疗效、安全性和心理状态。
方法 选本院2016年6月直到2017年6月接收的共100例伴有抑郁状态的精神分裂患者，以抽签法将其分为研究组50例和对照组50例；研究组行齐拉西酮和心理治疗的联合疗法，对照组行利培酮和心理治疗共同疗法，研究两组治疗影响。
结果 HAMD-17、PANDD研究组分数比对照组分低，其中HAMD-17两组比，研究组是（6.21±2.54）分，对照组（12.59±3.21）分，研究组的HAMD-17分低（P＜0.05）；总有效率对比研究组相比对照组高，其中研究组为94.00%（47/50），对照组72.00%（36/50），研究组总有效率高（P＜0.05）；不良反应比较，对照组比研究组反应率高，研究组为6.00%（3/50），对照组26.00%（13/50），对照组出现率高（P＜0.05）。
结论 齐拉西酮、心理治疗联合用在伴抑郁症状精神分裂症患者中疗效佳。

【Abstract】

[Abstract] Objective To analyze the clinical efficacy, safety and psychological status of Ziprasidone combined with psychotherapy in the treatment of schizophrenia complicated by depressive symptoms.
Methods A total of 100 cases with schizophrenia complicated by depression who had received treatment in our hospital between June 2016 and June 2017 were selected and divided into a study group and a control group by lot drawing method, with 50 cases in each group: the study group was given combined therapy of Ziprasidone and psychotherapy, whereas the control group received Risperidone and psychotherapy for treatment. The clinical effect of treatment in the two groups was compared.
Results Scores on HAMD-17 and PANDD in the study group were both shown to be lower than the control group, with HAMD-17 in the study group and the control group was respectively (6.21±2.54) and (12.59±3.21) (P<0.05); the total effective rate of treatment in the study group, which was 94.00% (47/50), was shown to be higher than the control group, which was 72.00% (36/50) (P<0.05); the incidence of adverse reactions in the control group, which was 26.00% (13/50), was shown to be higher than that in the study group, which was 6.00% (3/50) (P<0.05).
Conclusion   For schizophrenic patients with depressive symptoms, Ziprasidone combined with psychotherapy is with good curative effects.